Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Cancer Outcomes, Public Policy and Effectiveness Research Center, Yale University, New Haven, CT, USA.
JNCI Cancer Spectr. 2024 Jul 1;8(4). doi: 10.1093/jncics/pkae059.
High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510. Monthly costs were highest during the month of CAR-T therapy administration (median = $521 500), with median costs below $25 000 in all other 28-day intervals. Costs of CAR-T therapy use were substantial, largely driven by product acquisition. Future studies should examine the relationship between costs, access, and financial outcomes.
upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost/unit upfront cost upfront cost upfront cost in upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront cost upfront upfront
